What Tempus AI's latest 10-Q says: 8 signals
Tempus AI filed its latest 10-Q with the SEC on Jul 30, 2026. It discusses acquisition announced, AI investment and cash flow concern.
Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn
- Filed
- Jul 30, 2026
- Filings
- 2
- Signals
- 20
10-Q · latest 10
What Tempus AI's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 8 signals
Tempus to acquire Personalis, Inc., citing significant integration costs and operational risks.
The merger, announced July 20, 2026, will significantly increase operational complexity.
$76.8M
Potential termination fee for the merger agreement with Personalis, Inc.
AIPersonalis, Inc.
The company is undergoing a significant merger which will cause major integration challenges, potential loss of key employees, and disruption to ongoing business.
$76.8M
Potential termination fee for the merger agreement with Personalis, Inc.
Tempus raised $460M in capital via convertible senior notes in May 2026.
The company issued a significant amount of new debt, adding complexity to its capital structure and creating future obligations for servicing and potential conversion.
$460M
Aggregate principal amount of 0.00% Convertible Senior Notes due 2032 issued in May 2026.
U.S. Bank Trust Company, National Association
Company warns of liquidity risk from its $1.21B in convertible notes.
Tempus explicitly states that if noteholders elect to convert, the company may be required to settle in cash, which could adversely affect liquidity.
$1.2B
Total aggregate principal of 2030 Notes ($750M) and 2032 Notes ($460M).
Director Nadja West and CAO Ryan Bartolucci adopted new Rule 10b5-1 trading plans in Q2 2026.
The adoption of new, pre-planned stock selling arrangements by a board member and the Chief Accounting Officer are significant governance events.
Acquisition of Personalis reinforces strategic investment in AI and large-scale genomics data.
The merger with genomics firm Personalis, Inc.
AIgenomics
Tempus anticipates potential class action lawsuits related to its Personalis acquisition.
The company explicitly flags the high probability of securities class action and derivative lawsuits following the merger announcement.
Personalis, Inc.
- SEC EDGAR
10-Q
Filed · 12 signals
The U.S. Attorney's Office for the Eastern District of New York is investigating Tempus's compliance with federal laws related to billing, including the False Claims Act and Anti-Kickback statute.
Tempus is facing several lawsuits from Guardant Health alleging its core liquid biopsy products infringe on multiple patents.
liquid biopsyGuardant Health Inc.
A lawsuit filed on Feb 12, 2026, alleges violations of state privacy laws, creating significant legal risk and pressure to invest in data governance, compliance, and privacy-enhancing technologies to mitigate liability.
genetic information
Showing 10 of 20 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Tempus AI earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Actively procuring additional GPU capacity for large-scale AI model trainingThe company is doubling down on its AI foundation model, moving into the 'large compute' phase and actively seeking more GPU capacity. This represents a significant, immediate IT and cloud infrastructure spending initiative. | |
| Struggling with NGS sequencing failures and insufficient sample material (QNS)Leadership explicitly acknowledged that a percentage of their sequencing tests fail due to technical issues or lack of sufficient biological material. They are actively seeking technological solutions, like the newly acquired Paige AI, to mitigate this core operational problem. | |
| Aspires to an 'NVIDIA moment' by monetizing diagnostic algorithmsThe CEO's long-term vision is to move beyond wet lab services and achieve exponential growth by distributing and monetizing AI-driven diagnostic algorithms. This software-centric, scalable model underpins their heavy investments in data, AI, and compute infrastructure. | |
| Overcame significant sales force disruption, now focused on efficiencyThe CEO admitted that previous changes to the sales force 'caused havoc' but are now resolved. The current focus is on sales force efficiency and leveraging their integrated technology, indicating a receptiveness to tools that enhance sales productivity and effectiveness. | |
| Investing heavily in R&D for next-generation MRD assays and new clinical studies.The company is running new studies for a more sensitive tumor-naive MRD assay in lung cancer and CRC, indicating significant R&D spend. This focus on developing a highly competitive product portfolio creates needs for clinical trial support, data analysis tools, and lab technologies. | |
| Planning FDA submission for xF liquid biopsy test, a key strategic initiative.The company is preparing to file for FDA approval for its xF liquid biopsy test this year, a major regulatory and commercial initiative. This effort will require significant resources and is a critical step toward securing higher reimbursement (ADLT status) and driving future revenue growth. |
Signal API · MCP
Track Tempus AI with the Signal API
One POST /v1/companies/enrich call with tempus.com returns Tempus AI 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"tempus.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Tempus AI 10-Q
When did Tempus AI file its latest 10-Q?
What did Tempus AI disclose in its latest 10-Q?
What did Tempus AI say on its recent earnings calls?
Where can I read Tempus AI's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .